前列地尔联合特利加压素治疗肝硬化合并难治性腹水的临床价值研究

Study on the Clinical Value of Alprostadil and Terlipressin in the Treatment of Cirrhosis Complicated with Refractory Ascites

目的针对存在肝硬化合并难治性腹水的患者选择前列地尔联合特利加压素治疗,对其治疗效果展开分析。方法本研究纳入的研究对象均为我院在2016年1月至2018年12月这个时期当中收治的88例存在肝硬化合并难治性腹水的患者,将随机数字表应用于本研究分组中,取得对照组和研究组,对照组治疗药物为前列地尔,研究组治疗药物为前列地尔联合特利加压素,对比两组治疗效果。结果研究组各指标均存在优势,P<0.05。结论肝硬化合并难治性腹水属于一类比较严重的疾病,可以对其采取前列地尔联合特利加压素进行治疗,具有显著效果,明显减少患者的腹水量。

Objective To analyze the therapeutic effect of lithocirrhosis combined with refractory ascites in patients with alprostadil and terlipressin.Methods 88 patients with cirrhosis combined with refractory ascites who were admitted to our hospital between January 2016 and December 2018 were included in the study.The randomized numbers table was applied to the study group and the control group and the research group were obtained.The control group treated the drug as the alprostadil,and the group treated the drug as the alprostadil and the terlipressin,and compared the two groups of treatment results.Results All the indicators of the Study Group had advantages,P<0.05.Conclusion Cirrhosis combined with refractory ascites is a kind of serious disease,which can be treated with alpro stadil and terlipressin,which has significant effect and significantly reduces the amount of ascites in patients.